Additionally, the radiotracer is reported to have lower urinary excretion than traditionally used PSMA-PET agents, and the studies suggest an improved distinction between primary tumor and background bladder activity to aid in local tumor and lymph node identification [36,37]. Here, FOLH1 is linked to neoplasm.